Eli Lilly has announced that its new cancer drug for non-small-cell (squamous-cell) lung carcinoma has shown promise in trials for extending the life of patients in advanced stages for this form of cancer, when used in combination with conventional chemotherapy.
This is good news, yes? But nowhere in the article announcing this great news did I see any reference to a time factor. By how long was the life of patients extended? A few weeks? A few months? A few years? In fact the great news seemed to be that Eli Lilly's shares rose in trading as a result of the announcement, which is of little consequence to lung cancer patients, unless they happen to own shares in Eli Lilly.
Reported side effects included a rash (which could be severe) and possible blood clots, including pulmonary embolism. The side effects of the conventional chemotherapy in conjunction with which this drug is to be used are legion. The website collating side effects reports nine deaths directly related to the use of the drug.
I would like to see studies comparing the effectiveness of this drug and its cousins in treating stage-4 cancer against the effectiveness of the Domancic Method, the Bengston Method, and Kurt Peterson's cancer treatments, with respect to both longevity and quality of life.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment